Gyre Therapeutics (GYRE) Long-Term Investments (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Long-Term Investments for 11 consecutive years, with $107.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Long-Term Investments rose 66.46% year-over-year to $107.1 million; the TTM figure through Dec 2025 stood at $107.1 million (up 66.46% YoY), while the FY2025 annual figure was $107.1 million, up 66.46% from the prior year.
• Long-Term Investments climbed to $107.1 million in Q4 2025 per GYRE's latest filing, from $64.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $107.1 million in Q4 2025 and bottomed at $40.6 million in Q4 2022.
• Historically, Long-Term Investments has averaged $65.4 million across 4 years, with a median of $57.0 million in 2023.
• Annual changes were most pronounced in 2023 — Long-Term Investments grew 22.34% — and 2025, when it jumped 66.46%.
• Gyre Therapeutics' Long-Term Investments stood at $40.6 million in 2022, then gained by 22.34% to $49.7 million in 2023, then rose by 29.38% to $64.3 million in 2024, then soared by 66.46% to $107.1 million in 2025.
• Business Quant data shows GYRE's Long-Term Investments at $107.1 million in Q4 2025, $64.3 million in Q4 2024, and $49.7 million in Q4 2023.